----
Current ValuationThe current P/E ratio is -3.90, within the reasonable range, cheaper than 58.11% of the time in the past 3 years, and the industry ranks 43/74, the industry Median 0.31.
-3.9xP/E
$10.02Stock price
$-2.57Earnings per share
-3.9xP/E
Stock price$10.02Earnings per share$-2.57
Historical Valuation
P/E ratioTypical rangeMedian
- P/E ratio
- -3.32x
- Typical range
- -5.32x–-1.58x
Peer P/E ratio Comparison
It displays how the company's P/E ratio compares to top companies within its industry.
Industry median 0.31x
08162432
Industry P/E ratio Comparison
This shows the distribution of companies by P/E ratio range and their projected earnings per share growth for the next fiscal year.
Industry median 0.31x
0x30x60x90x120x150x
| Name/Symbol | |||
|---|---|---|---|
GHUSGuardant Health | -42.98x | 0.44% | $20.85B |
RDNTUSRadnet | -274.07x | 136.00% | $6.13B |
HIMSUSHims & Hers Health | -23.39x | 250.50% | $4.46B |
NEOUSNeogenomics | -67.95x | 71.60% | $2.19B |
AGLUSagilon health | -21.89x | 110.46% | $1.91B |
WGSUSGeneDx | -14.72x | 349.32% | $1.64B |
LMRIUSLumexa Imaging | -48.23x | 145.51% | $1.34B |
OPKUSOpko Health | -8.58x | 32.43% | $1.27B |
CSTLUSCastle Biosciences | -46.09x | 0.24% | $1.06B |
AONCUSAmerican Oncology Network | -- | -- | $753.97M |
FLGTUSFulgent Genetics | -7.92x | 42.64% | $720.27M |
SRTAUSStrata Critical Medical | -21.47x | 34.38% | $532.57M |
PREUSPrenetics Global | -6.29x | 11.12% | $295.38M |
GAMGUSGlobal Asset Management Group, Inc. | -351.59x | -- | $198.45M |
CORBFUSGlobal Cord Blood Corporation | -- | -- | $127.35M |
BDSXUSBiodesix | -3.90x | 39.25% | $105.72M |
NAKAUSNakamoto | -0.25x | 102.50% | $105.04M |
PARKUSPark Dental Partners | -28.92x | -- | $102.24M |
AIRSUSAirSculpt Tech | -6.06x | 5.26% | $56.96M |
EUDAUSEuda Health | -18.57x | 208.11% | $43.90M |
Risk Warning
Timeframes using financial data from S&P Global. The feature provides key metrics such as price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S) ratios, and dividend yield. For reference only and does not constitute investment advice.
